Analyst Actions -- 9/27/2011

 | Sep 27, 2011 | 1:00 PM EDT  | Comments
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

emc

,

ffiv

,

dltr

,

wms

,

lm

,

bax

,

bsx

,

abt

,

zmh

,

syk

,

clx

Abbott Laboratories downgraded at JP Morgan

ABT was downgraded from Overweight to Neutral, JP Morgan said. Valuation call, as the stock has outperformed its peers year-to-date.

-----

Accenture estimates lowered at Citigroup

ACN estimates lowered through 2012, Citigroup said.  Small adjustments due to negative FX moves.  Maintain $66 price target and Buy rating.

-----

Accretive Health rated new Buy at UBS

AH was initiated with a Buy rating, UBS said.  $29 price target.  Riding healthcare tailwinds to address a large market opportunity. 

-----

Alexion Pharmaceuticals numbers raised at Oppenheimer         

Shares of ALXN now seen reaching $74, according to Oppenheimer. Estimates also increased, as Solaris should continue to drive growth. Outperform rating.

-----

AMC Networks rated new Sell at Stifel

AMCX was initiated with a Sell rating, Stifel Nicolaus said. Valuation call, based on a $30 price target.

-----

Baxter upgraded at JP Morgan

BAX was upgraded from Neutral to Overweight, JP Morgan said. Sales growth should accelerate over the next several quarters.

-----

Boston Scientific upgraded at JP Morgan

BSX was upgraded from Underweight to Neutral, JP Morgan said. Valuation call, as the stock is down 34% since last January. Company sports an attractive 13% free cash flow yield.

-----

Bunge Limited upgraded at Citigroup

BG was upgraded from Hold to Buy, Citigroup said.  $88 price target.  See significant value following the 24% decline over the past two months. 

-----

Clorox upgraded at Caris

CLX was upgraded from Below Average to Average, Caris & Company said. $66 price target. Stock is attractive, following the Icahn-related selloff.

-----

Corn Products International estimates, target cut at Citigroup

Shares of CPO now seen reaching $68, according to Citigroup.  Estimates also lowered on FX headwinds.  Maintain Buy rating.

-----

Dollar Tree numbers increased at Morgan Stanley

DLTR estimates were raised through 2014, Morgan Stanley said. Company should continue to grow square footage and see better store traffic over the next several quarters. Overweight rating and new $86 price target.

-----

EMC target reduced at Morgan Stanley

Shares of EMC now seen reaching $33, according to Morgan Stanley. Macro weakness could hurt IT spending. In addition, the company is facing increased competition. Overweight rating.

-----

F5 Networks rated new Hold at Jefferies

Coverage of FFIV was started with a Hold rating, Jefferies said. Valuation call, based on a $70 price target.

-----

Freescale Semiconductor estimates lowered at Credit Suisse

FSL estimates were cut through 2012, Credit Suisse said. Company is seeing weaker industrial and networking demand. Outperform rating and $27 price target.

-----

Gartner rated new Neutral at Goldman

IT was initiated with a Neutral rating, Goldman Sachs said. $35 price target. Macro headwinds could hurt near-term growth.

-----

Genesis Energy upgraded at UBS

GEL was upgraded from Neutral to Buy, UBS said.  $27 price target.  Valuation call, along with strong financial metrics.

-----

Holly Energy upgraded at UBS

HEP was upgraded from Neutral to Buy, UBS said.  $55 price target.  Attractive valuation for stable business.

-----

Hunstman cut from Conviction Buy List at Goldman

HUN was removed from the Conviction Buy list, Goldman Sachs said. Estimates also lowered, as the sector is facing lower demand and currency/commodity headwinds. New $14 price target.

-----

Legg Mason numbers cut at Jefferies

Shares of LM now seen reaching $31, according to Jefferies. Estimates also reduced, given higher market volatility. Buy rating.

-----

Maximus rated new Market Outperform at JMP

MMS was initiated with a Market Perform rating, JMP Securities said. $41 price target. Company can continue to grow across the globe.

-----

Precision Drilling rated new Outperform at Credit Suisse

Coverage of PDS was started with an Outperform rating, Credit Suisse said. $16 price target. Canadian operations should drive growth over the next several quarters.

-----

Riverbed Technology rated new Underperform at Jefferies

RVBD was initiated with an Underperform rating, Jefferies said. $15 price target. WAN optimization market should see decelerating growth.

-----

Stryker upgraded at JP Morgan

SYK was upgraded to Overweight, JP Morgan said. Valuation call, as the stock is down 12% year-to-date.

-----

Vera Bradley rated new Buy at Jefferies

VRA was initiated with a Buy rating, Jefferies said. $50 price target. Company is still in the early stages of an attractive growth opportunity.

-----

WMS Industries downgraded at Sterne Agee

WMS was downgraded from Buy to Neutral, Sterne Agee said. $22 price target. Company lacks near-term catalysts.

-----

Zimmer downgraded at JP Morgan

ZMH was downgraded to Neutral, JP Morgan said. Company will likely see slower growth in the coming quarters/

Columnist Conversations

Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...
Market gets hit from impact of sanctions against Russia for second day in row but manages to rally a bit to en...
We took out some of the high end of support, but I'm still looking at this symmetrical pullback for entries on...
going into trading today roughly 37 million shares of X (US Steel) was held short.today big X has traded 27 mi...

BEST IDEAS

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.